Ziprasidone HCl monohydrate | 盐酸齐拉西酮水合物 | CP-88,059 | 5-HT/DA Receptor Antagonist

首页 / / / / Ziprasidone HCl monohydrate/佐帕司通

Ziprasidone HCl monohydrate/佐帕司通 {[allProObj[0].p_purity_real_show]}

货号：A473367 同义名： 盐酸齐拉西酮水合物;齐拉西酮盐酸盐一水合物 / CP-88,059; Ziprasidone (hydrochloride hydrate)

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Ziprasidone HCl monohydrate/佐帕司通化学结构
CAS号：138982-67-9

Ziprasidone HCl monohydrate/佐帕司通 3D分子结构
CAS号：138982-67-9

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Ziprasidone HCl monohydrate/佐帕司通纯度/质量文件产品仅供科研

货号：A473367 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]; • Cell, 2025. Ambeed. [ A122167 ]; • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]; • Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]; 更多 >

5-羟色胺受体亚型比较
多巴胺受体亚型比较

产品名称	5-HT ↓ ↑	5-HT1 ↓ ↑	5-HT2 ↓ ↑	5-HT3 ↓ ↑	5-HT5 ↓ ↑	5-HT6 ↓ ↑	5-HT7 ↓ ↑	其他靶点	纯度
Desvenlafaxine	++ 5-HT, Ki: 40.2 nM								98%
Lamotrigine	+ 5-HT (human platelets), IC50: 240 μM 5-HT (rat brain synaptosomes), IC50: 474 μM								98%
Venlafaxine	✔								99%
Fluvoxamine maleate	✔								99%
Iloperidone	✔								99%
Ziprasidone HCl	✔								98+%
Atomoxetine HCI	+ 5-HT, Ki: 77 nM								98%
Dapoxetine HCl	✔								97%
Trazodone	✔								98+%
Clomipramine HCl	✔								98%
Mirtazapine	✔								99+%
Escitalopram oxalate	+++ 5-HT, Ki: 0.89 nM								97%
Duloxetine	✔								97%
Sertraline HCl	++ 5-HT, Ki: 13 nM								98%
Citalopram HBr	+++ serotonin reuptake, IC50: 1.8 nM								98%
Latrepirdine 2HCl	✔							GluR	99%
Fluoxetine HCl	✔								99.5%
Paroxetine HCl	✔							AChR	99%
BMY 7378		++ 5-HT1A, pIC50: 6.4 5-HT1D, pIC50: 5.9	+ 5-HT2, pIC50: 5.5						97%
Flibanserin		+++ 5-HT1A, Ki: 1 nM	+ 5-HT2A, Ki: 49 nM						95%
LY310762		+ 5-HT1D, Ki: 249 nM							99%+
Cyclobenzaprine HCI			✔						99%
Blonanserin			+++ 5-HT2, Ki: 3.98 nM						99%
Cyproheptadine HCl			++++ 5-HT2, IC50: 0.6 nM						99+%
Olanzapine			✔						99+%
Pimavanserin hemitartrate			+++ 5-HT2A, pIC50: 8.7						99%
Ketanserin			+++ 5-HT2C (Human), Ki: 2.5 nM 5-HT2C (Rat), Ki: 50 nM						99%+
Loxapine succinate			++ 5-HT2 (human), Ki: 6.8 nM 5-HT2 (bovine), Ki: 6.6 nM						98%
Agomelatine			✔						98%
Clozapine			✔						98%
Amitriptyline			+ 5-HT2, Ki: 235 nM					SERT	99%
PRX-08066 maleate			+++ 5-HT2B, IC50: 3.4 nM						98+%
RS-127445			++++ 5-HT2B, pIC50: 10.4 5-HT2B, pKi: 9.5						99%+
Sarpogrelate HCl			++++ 5-HT2C, Kd: 1.1 nM 5-HT2A, Kd: 2.1 nM						98%
Tropisetron				✔					99%
Ramosetron HCl				++++ 5-HT3 receptor, Ki: 0.091 nM					98%
Ondansetron				✔					99%
Granisetron				✔					98%
Alosetron HCl				✔					98%
Ondansetron HCl dihydrate				✔					98%
VUF10166				++++ 5-HT3AB, Ki: 22 nM 5-HT3A, Ki: 0.04 nM					99%+
Azasetron HCl				++++ 5-HT3, IC50: 0.33 nM					99%
Asenapine maleate		+++ 5-HT1B, pKi: 8.4 5-HT1A, pKi: 8.6	++++ 5-HT2A, pKi: 9.75 5-HT2C, pKi: 10.46		+++ 5-HT5A, pKi: 8.84	++++ 5-HT6, pKi: 9.6	++++ 5-HT7, pKi: 9.94		97%
Risperidone		++ 5-HT1D, Ki: 84.6 nM 5-HT1B, Ki: 14.9 nM	++++ 5-HT2C, Ki: 12 nM 5-HT2A, Ki: 61.9 nM		+ 5-HT5A, Ki: 206 nM		++ 5-HT7, Ki: 6.6 nM		98%
SB 271046 HCl						+++ 5-HT6, pKi: 8.92			99%+
Intepirdine						++++ 5-HT6, pKi: 9.63			99%+
SB-269970 HCl							++ 5-HT7, pKi: 8.3		98+%
BRL 15572		++ 5-HT1B, pKi: 6.1 5-HT1D, pKi: 6	++ 5-HT2A, pKi: 6.6 5-HT2B, pKi: 6.2			+ 5-HT6, pKi: 5.9	+ 5-HT7, pKi: 6.3		95%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	D1 receptor ↓ ↑	D2 receptor ↓ ↑	D3 receptor ↓ ↑	D4 receptor ↓ ↑	D5 receptor ↓ ↑	DAT ↓ ↑	Dopamine receptor ↓ ↑	其他靶点	纯度
Penfluridol	+ Dopamine receptor, Ki: 1.6 μM								98%
Ansofaxine HCl	++ Dopamine receptor, IC50: 491 nM								99%
Tetrahydroberberine		+ D2 receptor, pKi: 6.08							98+%
Prochlorperazine Maleate		✔							98% (HPLC)
Olanzapine		✔							99+%
Trifluoperazine		++++ Dopamine D2 receptor, IC50: 1.1 nM							98%
Ropinirole HCl		++ D2 receptor, Ki: 29 nM							99%
Lurasidone		++++ D2 receptor, Ki: 1 nM							98%
Levosulpiride		✔							99+%
Pridopidine		✔							95%
Metoclopramide		✔					✔		99+%
Molindone HCl		✔							99%
Sulpiride		✔							99+%
Perospirone		++++ D2 receptor, Ki: 1.4 nM							99%
Perospirone HCl		++++ D2 receptor, Ki: 1.4 nM							99%
Phenothiazine		✔							98%
Pimozide	+ Dopamine D1 receptor, Ki: 6600 nM	+++ Dopamine D2 receptor, Ki: 3.0 nM	++++ Dopamine D3 receptor, Ki: 0.83 nM						98%
Rotundine	++ D1 receptor, IC50: 166 nM	+ D2 receptor, IC50: 1.47 μM	+ D3 receptor, IC50: 3.25 μM						98%
Domperidone		✔							99+%
ONC206		✔							99%
Pimethixene maleate	++ Dopamine D1 Receptor, pKi: 6.37	+++ Dopamine D2 Receptor, pKi: 8.19		++ Dopamine D4.4 Receptor, pKi: 7.54					97%
Loxapine succinate	++ D1 receptor (human), Ki: 26 nM D2 receptor (Human), Ki: 62 nM	++ D2 receptor (bovine), Ki: 26 nM D2 receptor (human), Ki: 24 nM		+++ D4 receptor (human), Ki: 7.5 nM					98%
Chlorprothixene	+++ D1 receptor, Ki: 18 nM	+++ D2 receptor, Ki: 2.96 nM	+++ D3 receptor, Ki: 4.56 nM		+++ D5 receptor, Ki: 9 nM				99%
SCH-23390 HCl	++++ D1 dopamine receptor, Ki: 0.2 nM				++++ D5 dopamine receptor, Ki: 0.3 nM				98%
MPP+ iodide						✔			97%
σ1 Receptor antagonist-1						+ DAT, pKi: 5.8			97%
Benztropine mesylate						++ DAT, IC50: 118 nM			98%
Azaperone							✔		98%
Ziprasidone HCl							✔		98+%
Paliperidone							✔		98%
Alizapride HCl							✔		99+%
Amisulpride							✔		98%
Quetiapine hemifumarate							✔	Adrenergic Receptor	98%
Clozapine N-oxide							✔		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Ziprasidone HCl monohydrate/佐帕司通生物活性

描述

Ziprasidone HCl H2O is a full antagonist of D2 receptors and of 5-HT2A receptors and is a partial agonist of 5-HT1A receptors, of 5-HT2C receptors and 5-HT1D receptors, used as an atypical antipsychoticfor the treatment of schizophrenia as well as acute mania and mixed states associated with bipolar disorder. Ziprasidone HCl has high affinity for rat (Ki: 3.4 nM)/human (2.5 nM) 5-HT1A receptors, 5-HT2A (0.42 nM), and dopamine D2 receptors (4.8 nM). Ziprasidone HCl is an inhibitor of norepinephrine reuptake^[2]. In vivo, ziprasidone antagonizes 5-HT2A receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D2 receptor antagonism. The compound is well tolerated in animals at doses producing effective dopamine antagonism in the brain^[3]. Ziprasidone exhibits dose proportional, linear changes in exposure and is hepatically metabolized primarily by aldehyde oxidase^[4]. Short-term treatment with intramuscular ziprasidone was effective and well tolerated in patients with acute agitation associated with psychosis^[5].

Ziprasidone HCl monohydrate/佐帕司通临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01185743	Schizophrenia ... 展开 >> Diabetes 收起 <<	Phase 4	Completed	-	Austria ... 展开 >> Medical University of Vienna Vienna, Austria, 1090 收起 <<
NCT00538629	-		Completed	-	-
NCT01598324	-		Terminated(Clinical trial from... 展开 >> which subjects were recruited closed to enrollment) 收起 <<	-	United States, Massachusetts ... 展开 >> McLean Hospital - McLean Imaging Center Belmont, Massachusetts, United States, 02478 收起 <<

Ziprasidone HCl monohydrate/佐帕司通参考文献

[1]Ravikiran A, Arthanareeswari M, et al. Nonisothermal kinetics analysis of the dehydration of ziprasidone hydrochloride monohydrate by thermogravimetry. Indian J Pharm Sci. 2013 May;75(3):361-4.

[2]Rollema H, Lu Y, Schmidt AW, Sprouse JS, Zorn SH. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000 Aug 1;48(3):229-37

[3]Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA 3rd, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995 Oct;275(1):101-13

[4]Patel NC, Keck PE Jr. Ziprasidone: efficacy and safety in patients with bipolar disorder. Expert Rev Neurother. 2006 Aug;6(8):1129-38

[5]Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2002;62(8):1217-51

Ziprasidone HCl monohydrate/佐帕司通实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.14mL

0.43mL

0.21mL

10.70mL

2.14mL

1.07mL

21.39mL

4.28mL

2.14mL

Ziprasidone HCl monohydrate/佐帕司通技术信息

CAS号	138982-67-9
分子式	C₂₁H₂₄Cl₂N₄O₂S
分子量	467.41
SMILES Code	O=C1CC2=CC(CCN3CCN(C4=NSC5=C4C=CC=C5)CC3)=C(Cl)C=C2N1.[H]Cl.O
MDL No.	MFCD00921885

别名	盐酸齐拉西酮水合物;齐拉西酮盐酸盐一水合物 ;CP-88,059; Ziprasidone (hydrochloride hydrate); CP 88059 hydrochloride monohydrate; Ziprasidone hydrochloride monohydrate
运输	蓝冰
InChI Key	ZCBZSCBNOOIHFP-UHFFFAOYSA-N
Pubchem ID	60853

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Inert atmosphere, room temperature

溶解方案

细胞实验：

DMSO: 25 mg/mL(53.49 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01185743	Schizophrenia ... 展开 >> Diabetes 收起 <<	Phase 4	Completed	-	Austria ... 展开 >> Medical University of Vienna Vienna, Austria, 1090 收起 <<
NCT00538629	-		Completed	-	-
NCT01598324	-		Terminated(Clinical trial from... 展开 >> which subjects were recruited closed to enrollment) 收起 <<	-	United States, Massachusetts ... 展开 >> McLean Hospital - McLean Imaging Center Belmont, Massachusetts, United States, 02478 收起 <<
NCT03011645	Cardiovascular Diseases	Phase 1	Enrolling by invitation	November 2022	United States, North Carolina ... 展开 >> Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT00288366	Schizophrenia ... 展开 >> Schizoaffective Disorder Bipolar Disorder 收起 <<	Not Applicable	Completed	-	United States, Tennessee ... 展开 >> Psychiatric Hospital at Vanderbilt Nashville, Tennessee, United States, 37212 收起 <<
NCT00197951	Depression An... 展开 >>ger Anxiety Alcoholism 收起 <<	Phase 3	Completed	-	Spain ... 展开 >> Unidad de Conductas Adictivas//Servicio de Psiquiatría//Hospital de la Santa Creu i Sant Pau Barcelona, Spain, 08025 收起 <<
NCT00159770	Schizophrenia ... 展开 >> Schizoaffective Disorder Psychotic Disorders 收起 <<	Phase 3	Completed	-	-
NCT01844700	-		Terminated(very slow recruitme... 展开 >>nt, no sufficient results) 收起 <<	-	-
NCT00538629	-		Completed	-	-
NCT01893229	Bipolar Disorder	Phase 4	Unknown	December 2015	China, Guangdong ... 展开 >> Guangzhou Psychiatric Hospital Enrolling by invitation Guangzhou, Guangdong, China, 510370 Guangzhou Psychiatric Hospital Recruiting Guangzhou, Guangdong, China, 510370 Contact: Guiyun Xu, M.D xuguiyun2908@hotmail.com Principal Investigator: Guiyun Xu, M.D 收起 <<
NCT01844700	High Risk MC4R Genotype ... 展开 >> Low Risk MC4R Genotype One Week or Less Antipsychotic Lifetime Exposure 收起 <<	Phase 4	Terminated(very slow recruitme... 展开 >>nt, no sufficient results) 收起 <<	-	United States, New York ... 展开 >> Zucker Hillside Hospital, Psychiatry Research Glen Oaks, New York, United States, 11004 收起 <<
NCT00297960	Healthy Male Volunteers	Phase 4	Completed	-	Austria ... 展开 >> Department of Clinical Pharmacology, Medical University Vienna Vienna, Austria, 1090 收起 <<
NCT01211522	Delirium Impa... 展开 >>ired Cognition Long Term Psychologic Disorders 收起 <<	Phase 3	Active, not recruiting	July 15, 2025	United States, Colorado ... 展开 >> Denver Health/University of Colorado Health Sciences Center Denver, Colorado, United States, 80204-4507 United States, Connecticut Yale University Medical Center New Haven, Connecticut, United States, 06520-8057 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202-2915 United States, Iowa University of Iowa Iowa City, Iowa, United States, 52242 United States, Maryland University of Maryland Medical Center Baltimore, Maryland, United States, 21201 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114-2696 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 United States, Michigan University of Michigan Health System Ann Arbor, Michigan, United States, 48109-5360 United States, New York Albert Einstein Medical College-Montefiore Medical Center Bronx, New York, United States, 10461 United States, North Carolina University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States, 27599-7248 Moses Cone Health System Greensboro, North Carolina, United States, 27410 United States, Ohio The Ohio State Medical Center Columbus, Ohio, United States, 43210-1228 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104-6205 United States, Tennessee Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232-8300 United States, Texas Baylor Health Care System Dallas, Texas, United States, 75206 United States, Washington University of Washington Seattle, Washington, United States, 98195-9472 收起 <<
NCT00148564	Schizophrenia	Phase 4	Completed	-	Germany ... 展开 >> Charité Universitaetsmedizin Berlin; Campus Charité Mitte; Dept. for Psychiatry and Psychotherapy Berlin, Germany, 10117 收起 <<
NCT02534363	Schizophrenia ... 展开 >> Psychotic Disorders 收起 <<	Phase 4	Completed	-	Spain ... 展开 >> University Hospital Marqués de Valdecilla Santander, Cantabria, Spain, 39008 收起 <<
NCT00141271	Bipolar Disorder	Phase 3	Completed	-	-
NCT00136994	Schizophrenia	Phase 3	Completed	-	Italy ... 展开 >> Pfizer Investigational Site Savigliano, Cuneo, Italy, 12038 Pfizer Investigational Site Campi Bisenzio, Firenze, Italy, 50013 Pfizer Investigational Site Sora, Frosinone, Italy, 3039 Pfizer Investigational Site Parma, PR, Italy, 43100 Pfizer Investigational Site S. Arsenio, Salerno, Italy, 84037 Pfizer Investigational Site Bologna, Italy, 40100 Pfizer Investigational Site Cagliari, Italy, 09100 Pfizer Investigational Site Caserta, Italy, 81100 Pfizer Investigational Site Chiari (bs), Italy, 25032 Pfizer Investigational Site Cremona, Italy, 26100 Pfizer Investigational Site Fidenza(pr), Italy, 43036 Pfizer Investigational Site Foggia, Italy, 71100 Pfizer Investigational Site Genova-sestri, Italy, 16154 Pfizer Investigational Site Genova, Italy, 16132 Pfizer Investigational Site Lecce, Italy, 73100 Pfizer Investigational Site Milano, Italy, 20142 Pfizer Investigational Site Modena, Italy, 41100 Pfizer Investigational Site Moncalieri(to), Italy, 10024 Pfizer Investigational Site Napoli, Italy, 80136 Pfizer Investigational Site Noto, Italy, 96017 Pfizer Investigational Site Orbassano (to), Italy, 10043 Pfizer Investigational Site Padova, Italy, 35128 Pfizer Investigational Site Palermo, Italy, 90145 Pfizer Investigational Site Perugia, Italy, 06100 Pfizer Investigational Site Pordenone, Italy, 33170 Pfizer Investigational Site Roma, Italy, 00149 Pfizer Investigational Site Sassari, Italy, 07100 Pfizer Investigational Site Senigallia (an), Italy, 60019 Pfizer Investigational Site Torino, Italy, 10126 Pfizer Investigational Site Torino, Italy, 10154 Pfizer Investigational Site Torrette Di Ancona (an), Italy, 60020 Pfizer Investigational Site Udine, Italy, 33100 Pfizer Investigational Site Verona, Italy, 37063 Pfizer Investigational Site Viareggio, Italy, 55049 收起 <<
NCT00239109	Schizophrenia	Phase 4	Completed	-	Spain ... 展开 >> Pfizer Investigational Site Bilbao, Vizcaya, Spain Pfizer Investigational Site Badajoz, Spain Pfizer Investigational Site Barcelona, Spain Pfizer Investigational Site Madrid, Spain Pfizer Investigational Site Salamanca, Spain Pfizer Investigational Site Sevilla, Spain Pfizer Investigational Site Zamora, Spain 收起 <<
NCT00141271	-		Completed	-	-
NCT00224315	Schizophrenia, Schizoaffective... 展开 >> Disorder 收起 <<	Phase 4	Completed	-	Germany ... 展开 >> Central Institute of Mental Health, Department of Psychiatry, Mannheim, BW, Germany, 68159 收起 <<
NCT00137020	Schizophrenia ... 展开 >> Psychotic Disorders 收起 <<	Phase 4	Completed	-	Egypt ... 展开 >> Pfizer Investigational Site Alexandria, Egypt Pfizer Investigational Site Assiut, Egypt Pfizer Investigational Site Cairo, Egypt Pfizer Investigational Site Tanta, Egypt Greece Pfizer Investigational Site Larissa, Mezourlo, Greece, 41110 Pfizer Investigational Site Athens, Greece, 11528 Pfizer Investigational Site Athens, Greece, 12462 Pfizer Investigational Site Athens, Greece, 15126 Jordan Pfizer Investigational Site Jordan, Jordan Kuwait Pfizer Investigational Site Kuwait, Kuwait, 13041 Lebanon Pfizer Investigational Site Beirut, Lebanon Saudi Arabia Pfizer Investigational Site Khobar, Saudi Arabia, 31451 South Africa Pfizer Investigational Site Garankuwa, Gauteng, South Africa, 0208 Pfizer Investigational Site Krugersdorp, Gauteng, South Africa, 1739 Pfizer Investigational Site Noordheuwel, Krugersdorp, Gauteng, South Africa, 1739 Pfizer Investigational Site Bellair, Durban, Kwa-Zulu Natal, South Africa, 4094 Pfizer Investigational Site Pinetown, Durban, Kwa-Zulu Natal, South Africa, 3600 Pfizer Investigational Site Observatory, Cape Town, Western Cape, South Africa, 7925 Turkey Pfizer Investigational Site Ankara, Turkey Pfizer Investigational Site Bursa, Turkey Pfizer Investigational Site Erzurum, Turkey Pfizer Investigational Site Istanbul, Turkey Pfizer Investigational Site Izmir, Turkey, 35340 Pfizer Investigational Site Izmir, Turkey Pfizer Investigational Site Manisa, Turkey Pfizer Investigational Site Sisli, Turkey United Arab Emirates Pfizer Investigational Site Dubai, United Arab Emirates 收起 <<
NCT00174447	Schizophrenia	Phase 3	Completed	-	France ... 展开 >> Pfizer Investigational Site Avignon, France, 84000 Pfizer Investigational Site Dole Saint Ylie, France, 39108 Pfizer Investigational Site Lievin, France, 62800 Pfizer Investigational Site Lyon Cedex, France, 69373 Pfizer Investigational Site Montfavet, France, 84143 Pfizer Investigational Site Orvault, France, 44700 Pfizer Investigational Site Rennes, France, 35000 Pfizer Investigational Site Saint Egreve Cedex, France, 38521 Pfizer Investigational Site Saint Remy, France, 70160 Pfizer Investigational Site Strasbourg, France, 67100 Pfizer Investigational Site Toulon Cedex, France, 83056 Pfizer Investigational Site Toulouse, France, 31000 Pfizer Investigational Site Toulouse, France, 31200 Pfizer Investigational Site Versailles, France, 78000 收起 <<
NCT00645372	Schizophrenia	Phase 3	Completed	-	China ... 展开 >> Pfizer Investigational Site Beijing, China, 100083 Pfizer Investigational Site Beijing, China, 100088 Pfizer Investigational Site Guangzhou, China, 510370 Pfizer Investigational Site Nanjing, China, 210029 Pfizer Investigational Site Shanghai, China, 200030 收起 <<
NCT00229385	Schizophrenia ... 展开 >> Obsessive Compulsive Disorder 收起 <<	Not Applicable	Completed	-	Israel ... 展开 >> Chaim Sheba Medical Center Ramat-Gan, Israel, 52621 收起 <<
NCT00174447	-		Completed	-	-
NCT00159757	Schizophrenia	Phase 4	Terminated(See Detailed Descri... 展开 >>ption for Termination Reason) 收起 <<	-	Hungary ... 展开 >> Pfizer Investigational Site Budapest, Hungary Pfizer Investigational Site Debrecen, Hungary Pfizer Investigational Site Esztergom, Hungary Pfizer Investigational Site Kecskemet, Hungary Pfizer Investigational Site Kistarcsa, Hungary Pfizer Investigational Site Pecs, Hungary Pfizer Investigational Site Szekesfehervar, Hungary Pfizer Investigational Site Tatabanya, Hungary 收起 <<
NCT00181922	Bipolar Disorder ... 展开 >> Mania 收起 <<	Phase 4	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Massachusetts General Hospital Cambridge, Massachusetts, United States, 02138 收起 <<
NCT00143351	Schizophrenia	Phase 3	Completed	-	Italy ... 展开 >> Pfizer Investigational Site Vicenza, Bassano Del Grappa, Italy, 36061 Pfizer Investigational Site Citta' Di Castello, Perugia, Italy, 06012 Pfizer Investigational Site Bari, Italy, 70100 Pfizer Investigational Site Brescia, Italy, 25100 Pfizer Investigational Site Catania, Italy, 95123 Pfizer Investigational Site Guardiagrele (ch), Italy, 66016 Pfizer Investigational Site Messina, Italy, 98100 Pfizer Investigational Site Parma, Italy, 43100 Pfizer Investigational Site Roma, Italy, 00100 Pfizer Investigational Site Roma, Italy, 00135 Pfizer Investigational Site Roma, Italy, 00137 Pfizer Investigational Site Sassari, Italy, 07100 Pfizer Investigational Site Terni, Italy Pfizer Investigational Site Torino, Italy, 10126 Pfizer Investigational Site Trieste, Italy, 34126 Pfizer Investigational Site Verona, Italy, 37100 收起 <<
NCT00265330	Bipolar Disorder	Phase 3	Completed	-	-
NCT01260116	-		Unknown	March 2012	-
NCT03211897	-		Completed	-	United States, Minnesota ... 展开 >> Hennepin County Medical Center Minneapolis, Minnesota, United States, 55415 收起 <<
NCT02526030	Schizophrenia ... 展开 >> Psychotic Disorders 收起 <<	Phase 4	Completed	-	Spain ... 展开 >> University Hospital Marqués de Valdecilla Santander, Cantabria, Spain, 39008 收起 <<
NCT00199940	Schizophrenia ... 展开 >> Affective Disorders Psychotic Disorder Psychotic Mood Disorder 收起 <<	Phase 4	Completed	-	-
NCT00338949	Schizophrenia ... 展开 >> Metabolic Syndrome X Insulin Resistance 收起 <<	Phase 4	Completed	-	United States, California ... 展开 >> VA San Diego Healthcare System San Diego, California, United States, 92161 收起 <<
NCT00257166	-		Completed	-	-
NCT00205725	Schizophrenia ... 展开 >> Type 2 Diabetes Mellitus 收起 <<	Not Applicable	Completed	-	United States, Missouri ... 展开 >> Washington University School of Medicine, Psychiatry Dept. St. Louis, Missouri, United States, 63110 收起 <<
NCT00634348	Schizophrenia	Phase 4	Completed	-	-
NCT02305823	Schizophrenia ... 展开 >> Psychotic Disorders 收起 <<	Phase 4	Completed	-	Spain ... 展开 >> University Hospital Marques de Valdecilla Santander, Cantabria, Spain, 39008 收起 <<
NCT00248261	-		Terminated(High rate of early ... 展开 >>drop-outs) 收起 <<	-	Germany ... 展开 >> UKE, Dept. of Psychiatry and Psychotherapy Hamburg, Germany, 2ß246 收起 <<
NCT01157559	First Episode Psychosis	Phase 4	Completed	-	Korea, Republic of ... 展开 >> Department of Psychiatry, Chonbuk national University Hospital Jeonju, Korea, Republic of Heo psychiatric Hospital Jeonju, Korea, Republic of Jeonju Jesus Hospital Jeonju, Korea, Republic of 收起 <<
NCT00257166	Bipolar Disorder	Phase 3	Completed	-	-
NCT00418171	Schizophrenia	Phase 4	Completed	-	United States, California ... 展开 >> Pfizer Investigational Site San Bernardino, California, United States United States, Hawaii Pfizer Investigational Site Aiea, Hawaii, United States United States, Illinois Pfizer Investigational Site Schaumburg, Illinois, United States United States, Oregon Pfizer Investigational Site Grants Pass, Oregon, United States United States, West Virginia Pfizer Investigational Site Whitehall, West Virginia, United States 收起 <<
NCT00786318	Psychosis Agi... 展开 >>tation Delirium 收起 <<	Phase 4	Withdrawn(Sponsor terminated)	July 2011	United States, District of Col... 展开 >>umbia The George Washington University Medical Center, Dept of Emergency Medicine Washington, D.C., District of Columbia, United States, 20037 收起 <<
NCT00340379	Affective Disorders	Phase 2 Phase 3	Completed	-	United States, California ... 展开 >> University of Southern California Los Angeles, California, United States, 90033 Egypt Alexandria University Alexandria, Egypt India National Institute of Mental Health and Neuroscience Bangalore, India, 560029 收起 <<
NCT00265330	-		Completed	-	-
NCT00340379	-		Completed	-	-
NCT00351000	Schizophrenia	Phase 4	Completed	-	United States, Massachusetts ... 展开 >> Freedom Trail Clinic Boston, Massachusetts, United States, 02114 收起 <<
NCT00645515	Schizophrenia	Phase 3	Terminated(This study was term... 展开 >>inated on November 20, 2003 because of poor recruitment. This study was not terminated due to safety/efficacy.) 收起 <<	-	Spain ... 展开 >> Pfizer Investigational Site Bilbao, Vizcaya, Spain, 48010 Pfizer Investigational Site Getxo, Vizcaya, Spain, 48990 Pfizer Investigational Site Madrid, Spain, 28007 收起 <<
NCT00649844	Schizophrenia	Phase 3	Completed	-	Italy ... 展开 >> Pfizer Investigational Site Citta' Di Castello, Perugia, Italy, 06012 Pfizer Investigational Site Bassano Del Grappa, Vicenza, Italy, 36061 Pfizer Investigational Site Bari, Italy, 70124 Pfizer Investigational Site Brescia, Italy, 25100 Pfizer Investigational Site Cagliari, Italy, 09045 Pfizer Investigational Site Cagliari, Italy, 09124 Pfizer Investigational Site Catania, Italy, 95123 Pfizer Investigational Site Firenze, Italy, 50134 Pfizer Investigational Site Guardiagrele (ch), Italy, 66016 Pfizer Investigational Site Messina, Italy, 98100 Pfizer Investigational Site Montichiari (brescia), Italy, 25018 Pfizer Investigational Site Napoli, Italy, 80131 Pfizer Investigational Site Parma, Italy, 43100 Pfizer Investigational Site Reggio Calabria, Italy, 89100 Pfizer Investigational Site Roma, Italy, 00135 Pfizer Investigational Site Roma, Italy, 00137 Pfizer Investigational Site Sassari, Italy, 07100 Pfizer Investigational Site Siena, Italy, 53100 Pfizer Investigational Site Torino, Italy, 10126 Pfizer Investigational Site Trieste, Italy, 34126 Pfizer Investigational Site Verona, Italy, 37126 收起 <<
NCT00282464	Bipolar Disorder	Phase 3	Completed	-	-
NCT00351000	-		Completed	-	-
NCT00282464	-		Completed	-	-
NCT02075047	Bipolar Disorder	Phase 3	Recruiting	October 4, 2020	-
NCT00145444	Schizophrenia ... 展开 >> Psychotic Disorders 收起 <<	Phase 3	Completed	-	Belgium ... 展开 >> Pfizer Investigational Site Antwerpen, Belgium, B-2060 Pfizer Investigational Site Duffel, Belgium, B-2570 Pfizer Investigational Site Kortenberg, Belgium, B-3070 Netherlands Pfizer Investigational Site Ermelo, Netherlands, NL-3851 PB Pfizer Investigational Site Groningen, Netherlands, NL-9713 GZ Pfizer Investigational Site Nijmegen, Netherlands, NL-6525 GC Pfizer Investigational Site Utrecht, Netherlands, 3584 CX 收起 <<
NCT00312494	-		Completed	-	-
NCT00257192	Schizophrenia	Phase 3	Terminated(Please see Detailed... 展开 >> Description for termination reason.) 收起 <<	-	-
NCT00329108	-		Terminated(Please see Brief Su... 展开 >>mmary for Termination Reason.) 收起 <<	-	-
NCT00257192	-		Terminated(Please see Detailed... 展开 >> Description for termination reason.) 收起 <<	-	-
NCT00208208	Posttraumatic Stress Disorder ... 展开 >> Post-Traumatic Stress Disorder PTSD 收起 <<	Phase 4	Completed	-	United States, Nebraska ... 展开 >> Creighton University Psychiatry and Research Center Omaha, Nebraska, United States, 68131 收起 <<
NCT00312494	Bipolar Disorder	Phase 3	Completed	-	-
NCT00329108	Acute Mania B... 展开 >>ipolar Disorder, Manic 收起 <<	Phase 4	Terminated(Please see Brief Su... 展开 >>mmary for Termination Reason.) 收起 <<	-	Germany ... 展开 >> Pfizer Investigational Site Aachen, Germany, 52074 Pfizer Investigational Site Augsburg, Germany, 86156 Pfizer Investigational Site Freiburg, Germany, 79104 Greece Pfizer Investigational Site Athens, Greece, 124 62 Italy Pfizer Investigational Site S. Arsenio, Salerno, Italy, 84037 Pfizer Investigational Site Bari, Italy, 70100 Pfizer Investigational Site Guardiagrele (CH), Italy, 66016 Pfizer Investigational Site Lido di Camaiore (LU), Italy, 55043 Pfizer Investigational Site Partinico (Pa), Italy, 90047 Pfizer Investigational Site Perugia, Italy, 06127 Pfizer Investigational Site Siena, Italy, 53100 Pfizer Investigational Site Torino, Italy, 10126 Pfizer Investigational Site Trieste, Italy, 34126 Spain Pfizer Investigational Site Terrassa, Barcelona, Spain, 08227 Pfizer Investigational Site Alava, Vitoria, Spain, 01004 Pfizer Investigational Site Granada, Spain, 18014 Pfizer Investigational Site Malaga, Spain, 29009 Turkey Pfizer Investigational Site Ankara, Turkey, 06100 Pfizer Investigational Site Istanbul, Turkey, 34440 收起 <<
NCT01117220	Bipolar Disorder	Phase 3	Withdrawn	April 2011	-
NCT00821444	Healthy	Phase 1	Completed	-	United States, Connecticut ... 展开 >> Pfizer Investigational Site New Haven, Connecticut, United States, 06511-5473 收起 <<
NCT01172652	Bipolar Disorder ... 展开 >> Panic Disorder Generalized Anxiety Disorder 收起 <<	Phase 4	Completed	-	United States, California ... 展开 >> VA Palo Alto Health Care System & Stanford School of Medicine Palo Alto, California, United States, 94304 United States, Florida University of South Florida Institute for Research in Psychiatry Tampa, Florida, United States, 33613 United States, Ohio Lindner Center of Hope University of Cincinnati Medical Center Mason, Ohio, United States, 45040 收起 <<
NCT00635700	-		Completed	-	-
NCT00635921	Borderline Personality Disorde... 展开 >>r 收起 <<	Phase 2	Completed	-	Spain ... 展开 >> Department of Psychiatry, Sta. Creu and St. Pau Hospital Barcelona., Spain, 08025 收起 <<
NCT00265382	Schizophrenia	Phase 3	Terminated(Please see Detailed... 展开 >> Description for termination reason.) 收起 <<	-	-
NCT00421954	-		Completed	-	-
NCT00421954	Schizophreniform Disorder ... 展开 >> Schizoaffective Disorder Psychosis Depressive Disorder, Major Bipolar Disorder 收起 <<	Phase 3	Completed	-	United States, New York ... 展开 >> NYSPI New York, New York, United States, 10032 收起 <<
NCT00676429	Conduct Disorder ... 展开 >> Oppositional Defiant Disorder 收起 <<	Phase 2	Completed	-	Germany ... 展开 >> University Hospital Freiburg, Dep. for Child & Adolescent Psychiatry Freiburg, Germany, D-79104 收起 <<
NCT00818298	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Not Applicable	Completed	-	Canada, Ontario ... 展开 >> Centre for Addiction and Mental Health - PET Centre Toronto, Ontario, Canada, M5T 1R8 收起 <<
NCT00723606	-		Completed	-	-
NCT00633399	-		Completed	-	-
NCT00650429	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 4	Completed	-	Mexico ... 展开 >> Pfizer Investigational Site Monterrey, Nuevo Leon, Mexico, 64800 Pfizer Investigational Site DF, Mexico, 14420 Pfizer Investigational Site Mexico City, Mexico, 14050 Pfizer Investigational Site Mexico D F, Mexico, 14269 收起 <<
NCT00265382	-		Terminated(Please see Detailed... 展开 >> Description for termination reason.) 收起 <<	-	-
NCT00644800	Schizophrenia ... 展开 >> Mania Delusional Disorder Acute Exacerbation of Psychosis 收起 <<	Phase 4	Completed	-	Brazil ... 展开 >> Pfizer Investigational Site Salvador, Bahia, Brazil, 41180-000 Pfizer Investigational Site Fortaleza, Ceara, Brazil, 60175-270 Pfizer Investigational Site Belo Horizonte, MG, Brazil, 30150-270 Pfizer Investigational Site Curitiba, PR, Brazil Pfizer Investigational Site Rio de Janeiro, RJ, Brazil Pfizer Investigational Site Sao Goncalo, RJ, Brazil Pfizer Investigational Site Jardim Santa Monica Sn, Salvador - Ba, Brazil, 40340-720 Pfizer Investigational Site Sao Paulo, SP, Brazil 收起 <<
NCT00633399	Major Depressive Disorder	Phase 2	Completed	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Massachusetts Massachusetts General Hospital- Depression Clinical and Research Program Boston, Massachusetts, United States, 02114 收起 <<
NCT01124877	Bipolar Disorder	Phase 3	Withdrawn	October 2011	-
NCT00635700	Psychosis Prodrome	Phase 2	Completed	-	United States, California ... 展开 >> University of California at San Diego La Jolla, California, United States, 92093 University of California at Los Angeles Los Angeles, California, United States, 90095 University of California, San Francisco San Francisco, California, United States, 94143 United States, Connecticut Yale University School of Medicine New Haven, Connecticut, United States, 06519 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Massachusetts Beth Israel Deaconess Hospital Boston, Massachusetts, United States, 02215 University of Massachusetts Worcester, Massachusetts, United States, 01604 United States, Michigan Wayne State University School of Medicine Detroit, Michigan, United States, 48201 United States, New York North Shore, Long Island Jewish Health System Glen Oaks, New York, United States, 11004 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 Canada, Alberta University of Calgary Calgary, Alberta, Canada, T2N2T9 收起 <<
NCT00645229	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 3	Terminated(Please see Detailed... 展开 >> Description for termination reason.) 收起 <<	-	Portugal ... 展开 >> Pfizer Investigational Site Lisboa, Portugal, 1600-219 收起 <<
NCT00723606	Schizophrenia	Phase 3	Completed	-	China, Hebei ... 展开 >> Pfizer Investigational Site Baoding, Hebei, China, 071000 China, Hubei Pfizer Investigational Site Wuhan, Hubei, China, 430060 China, Yunnan Pfizer Investigational Site Kunming, Yunnan, China, 650032 China Pfizer Investigational Site Beijing, China, 100083 Pfizer Investigational Site Beijing, China, 100088 Pfizer Investigational Site Chang Sha, China, 410011 Pfizer Investigational Site Guangzhou, China, 510370 Pfizer Investigational Site Nanjing, China, 210029 Pfizer Investigational Site Xi'an, China 收起 <<
NCT00406315	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 4	Completed	-	-
NCT00280566	-		Completed	-	-
NCT00406315	-		Completed	-	-
NCT00139737	-		Completed	-	-
NCT00139737	Schizophrenia	Phase 3	Completed	-	-
NCT00280566	Bipolar Mania ... 展开 >> Bipolar Disorder 收起 <<	Phase 3	Completed	-	-
NCT00490542	Bipolar Disorder ... 展开 >> Bipolar Depression Depression 收起 <<	Phase 2	Completed	-	United States, Illinois ... 展开 >> Northwestern University Chicago, Illinois, United States, 60201 United States, Massachusetts Tufts University Boston, Massachusetts, United States, 02111 Cambridge Health Alliance Cambridge, Massachusetts, United States, 02139 United States, North Carolina Duke University Durham, North Carolina, United States, 27704 收起 <<
NCT00490542	-		Completed	-	-
NCT00458211	-		Completed	-	-
NCT00454883	-		Completed	-	-
NCT00645320	Pyschotic Disorders	Phase 4	Completed	-	Brazil ... 展开 >> Pfizer Investigational Site Salvador, Bahia, Brazil, 41180-000 Pfizer Investigational Site Fortaleza, Ceara, Brazil, 60175-270 Pfizer Investigational Site Belo Horizonte, MG, Brazil, 30150-270 Pfizer Investigational Site Curitiba, PR, Brazil Pfizer Investigational Site Rio de Janeiro, RJ, Brazil Pfizer Investigational Site Jardim Santa Monica Sn, Salvador - Ba, Brazil, 40340-720 Pfizer Investigational Site Sao Paulo, SP, Brazil Pfizer Investigational Site Rio de Janeiro Rj, Brazil, 22640-100 收起 <<
NCT00483548	Bipolar Disorder ... 展开 >> Depression, Bipolar 收起 <<	Phase 3	Completed	-	-
NCT00215150	Social Anxiety Disorder	Phase 2	Completed	-	United States, North Carolina ... 展开 >> Duke University Medical Center Durham, North Carolina, United States, 27701 Duke University Medical Center Durham, North Carolina, United States, 27710 收起 <<
NCT00215150	-		Completed	-	-
NCT00472641	-		Completed	-	-
NCT00225498	Schizophrenia	Not Applicable	Completed	-	United States, New York ... 展开 >> The Zucker Hillside Hospital Glen Oaks, New York, United States, 11004 收起 <<
NCT00208559	Autism	Phase 2	Completed	-	United States, Pennsylvania ... 展开 >> Drexel University College of Medicine at Friends Hospital Philadelphia, Pennsylvania, United States, 19124 收起 <<
NCT00483548	-		Completed	-	-
NCT00225498	-		Completed	-	-
NCT00910988	Hyperglycemia ... 展开 >> Hyperlipidemia 收起 <<	Not Applicable	Completed	-	United States, Missouri ... 展开 >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 收起 <<
NCT00910988	-		Completed	-	-
NCT00374543	Generalized Anxiety Disorder ... 展开 >> Bipolar Disorder 收起 <<	Phase 4	Terminated(Recruitment goal co... 展开 >>uld not be achieved) 收起 <<	-	United States, Massachusetts ... 展开 >> Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital Boston, Massachusetts, United States, 02114 收起 <<
NCT01168674	Depression Bi... 展开 >>polar Disorder 收起 <<	Phase 4	Completed	-	-
NCT00472641	Bipolar Disorder	Phase 4	Completed	-	United States, California ... 展开 >> Stanford University School of Medicine Stanford, California, United States, 94305 收起 <<
NCT01168674	-		Completed	-	-
NCT00458211	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 4	Completed	-	United States, New York ... 展开 >> Bronx Psychiatric Center Bronx, New York, United States, 10461 Buffalo Psychiatric Center Buffalo, New York, United States, 14213 收起 <<
NCT00650611	Schizophrenia ... 展开 >> Bipolar Disorder Schizoaffective Disorder 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Pfizer Investigational Site San Diego, California, United States, 92111 United States, Florida Pfizer Investigational Site Altamonte Springs, Florida, United States, 32701 United States, Illinois Pfizer Investigational Site Libertyville, Illinois, United States, 60048 United States, Kentucky Pfizer Investigational Site Lexington, Kentucky, United States, 40509 United States, Massachusetts Pfizer Investigational Site Belmont, Massachusetts, United States, 02478 Pfizer Investigational Site Brighton, Massachusetts, United States, 02135 United States, Nevada Pfizer Investigational Site Las Vegas, Nevada, United States, 89103 Pfizer Investigational Site Las Vegas, Nevada, United States, 89117 Pfizer Investigational Site Las Vegas, Nevada, United States, 89128 United States, New Jersey Pfizer Investigational Site Turnersville, New Jersey, United States, 08012 United States, Ohio Pfizer Investigational Site Cincinnati, Ohio, United States, 45224 Pfizer Investigational Site Cincinnati, Ohio, United States, 45229 Pfizer Investigational Site Cincinnati, Ohio, United States, 45267-0559 Pfizer Investigational Site Cleveland, Ohio, United States, 44106 United States, Pennsylvania Pfizer Investigational Site Philadelphia, Pennsylvania, United States, 19104-3309 United States, Washington Pfizer Investigational Site Kirkland, Washington, United States, 98033 Pfizer Investigational Site Kirkland, Washington, United States, 98034 收起 <<
NCT00748566	Schizophrenia and Disorders Wi... 展开 >>th Psychotic Features 收起 <<	Phase 4	Terminated(See Detailed Descri... 展开 >>ption) 收起 <<	-	Canada, Alberta ... 展开 >> Pfizer Investigational Site Calgary, Alberta, Canada, T2N 2T9 Pfizer Investigational Site Calgary, Alberta, Canada, T2N 4Z6 Pfizer Investigational Site Medicine Hat, Alberta, Canada, T1A 4C2 Pfizer Investigational Site Medicine Hat, Alberta, Canada, T1B 4E7 Pfizer Investigational Site Red Deer, Alberta, Canada, T4N 1T6 Canada, British Columbia Pfizer Investigational Site Penticton, British Columbia, Canada, V2A 4M4 Pfizer Investigational Site Victoria, British Columbia, Canada, V8R 4Z3 Canada, Manitoba Pfizer Investigational Site Winnipeg, Manitoba, Canada, R3A 1R9 Pfizer Investigational Site Winnipeg, Manitoba, Canada, R3E 3N4 Pfizer Investigational Site Winnipeg, Manitoba, Canada, R3K 2E2 Pfizer Investigational Site Winnipeg, Manitoba, Canada, R3P 0N5 Canada, New Brunswick Pfizer Investigational Site Bathurst, New Brunswick, Canada, E2A 2Z6 Canada, Newfoundland and Labrador Pfizer Investigational Site St. John's, Newfoundland and Labrador, Canada, A1E 4J8 Canada, Nova Scotia Pfizer Investigational Site Halifax, Nova Scotia, Canada, B3H 2E2 Pfizer Investigational Site Sydney, Nova Scotia, Canada, B1P 1C6 Pfizer Investigational Site Sydney, Nova Scotia, Canada, B1P 1E1 Canada, Ontario Pfizer Investigational Site Burlington, Ontario, Canada, L7R 4E2 Pfizer Investigational Site Chatham, Ontario, Canada, N7L 1B7 Pfizer Investigational Site Kingston, Ontario, Canada, K7L 4X3 Pfizer Investigational Site London, Ontario, Canada, N6A 4G5 Pfizer Investigational Site Markham, Ontario, Canada, L6B 1A1 Pfizer Investigational Site Mississauga, Ontario, Canada, L5M 4N4 Pfizer Investigational Site Ottawa, Ontario, Canada, K1H 8K7 Pfizer Investigational Site Sudbury, Ontario, Canada, P3E 1X3 Pfizer Investigational Site Toronto, Ontario, Canada, M5T 1R8 Pfizer Investigational Site Toronto, Ontario, Canada, M6J 1H4 Pfizer Investigational Site Windsor, Ontario, Canada, N9C 3Z4 Canada, Quebec Pfizer Investigational Site Montreal, Quebec, Canada, H1N 3M5 Pfizer Investigational Site Montreal, Quebec, Canada, H1N 3V2 Pfizer Investigational Site Montreal, Quebec, Canada, H3A 1A1 Pfizer Investigational Site Verdun, Quebec, Canada, H4H 1R3 Canada, Saskatchewan Pfizer Investigational Site Saskatoon, Saskatchewan, Canada, S7K 3H3 收起 <<
NCT00374543	-		Terminated(Recruitment goal co... 展开 >>uld not be achieved) 收起 <<	-	-
NCT01053429	-		Completed	-	-
NCT00649064	Schizoaffective Disorder ... 展开 >> Schizophrenia 收起 <<	Phase 4	Completed	-	Taiwan ... 展开 >> Pfizer Investigational Site Changhua, Taiwan Pfizer Investigational Site Tainan, Taiwan Pfizer Investigational Site Taipei, Taiwan 收起 <<
NCT00538642	Schizophrenia ... 展开 >> Schizoaffective Disorder Bipolar Disorder 收起 <<	Not Applicable	Completed	-	United States, Texas ... 展开 >> The University of Texas Health Science Center At San Antonio San Antonio, Texas, United States, 78229 收起 <<
NCT01006551	Schizophrenia	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Harvard University Medford, Massachusetts, United States, 02155 United States, North Carolina University of North Carolina, Chapel Hill Chapel Hill, North Carolina, United States, 27599 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 United States, Washington University of Washington Seattle, Washington, United States, 98125 收起 <<
NCT01053429	-		Completed	-	-
NCT00579670	-		Completed	-	Greece ... 展开 >> Pfizer Investigational Site Athens, Greece, 12461 Pfizer Investigational Site Chaidari, Greece, 124 61 Pfizer Investigational Site Chaidari, Greece, 12461 Pfizer Investigational Site Chaidari, Greece, 12462 Pfizer Investigational Site Corfu, Greece, 49100 Pfizer Investigational Site Crete, Greece, 731-00 Pfizer Investigational Site Giannitsa, Greece, 58100 Pfizer Investigational Site Haidari, Greece, 12461 Pfizer Investigational Site Kalamata, Greece, 24100 Pfizer Investigational Site Katerini, Greece, 60100 Pfizer Investigational Site Kozani, Greece, 50100 Pfizer Investigational Site Kozani, Greece Pfizer Investigational Site Lamia, Greece, 35100 Pfizer Investigational Site Larisa, Greece Pfizer Investigational Site Patra, Greece, 26000 Pfizer Investigational Site Patra, Greece, 26001 Pfizer Investigational Site Thessaloniki, Greece, 564-29 Pfizer Investigational Site Thessaloniki, Greece, 56430 Pfizer Investigational Site Thessaloniki, Greece, 57010 Pfizer Investigational Site Volos, Greece, 38222 收起 <<
NCT00403546	Schizophrenia	Phase 3	Completed	-	United States, Georgia ... 展开 >> Medical College of Georgia Augusta, Georgia, United States, 30912 United States, Massachusetts Corrigan Mental Health Center Fall River, Massachusetts, United States, 02720 United States, Michigan Touchstone innovare Grand Rapids, Michigan, United States, 49503 United States, New Mexico University of New Mexico Albuquerque, New Mexico, United States, 87131 United States, New York SUNY Downstate Medical Center Brooklyn, New York, United States, 11203 The Lieber Center for Schizophrenia Research - Columbia University New York, New York, United States, 10032 Nathan Kline Institute Orangeburg, New York, United States, 10962 United States, North Carolina Duke University - John Umstead Hospital Butner, North Carolina, United States, 27509 United States, Texas The Mech Center Plano, Texas, United States, 75024 收起 <<
NCT00579670	-		Completed	-	-
NCT00538642	-		Completed	-	-
NCT01293825	Medication Adherence ... 展开 >> Bipolar Disorder 收起 <<	Phase 4	Completed	-	United States, Ohio ... 展开 >> University Hospitals Case Medical Center Cleveland, Ohio, United States, 44106 收起 <<
NCT00237666	Bipolar II Disorder ... 展开 >> Major Depressive Episode 收起 <<	Phase 4	Completed	-	United States, New York ... 展开 >> Medical Research Network, L.L.C. New York, New York, United States, 10024 United States, Texas The Mech Center Plano, Texas, United States, 75024 收起 <<
NCT00748566	-		Terminated(See Detailed Descri... 展开 >>ption) 收起 <<	-	-
NCT03768726	Bipolar Disorder	Phase 3	Not yet recruiting	September 7, 2020	-
NCT00403546	-		Completed	-	-
NCT00395031	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 2 Phase 3	Completed	-	United States, New York ... 展开 >> Manhattan Psychiatric Center New York, New York, United States, 10035 收起 <<
NCT00237666	-		Completed	-	-
NCT00622739	Bipolar Disorder	Phase 4	Completed	-	United States, Texas ... 展开 >> UT Southwestern Medical Center Dallas, Texas, United States, 75390 收起 <<
NCT01293825	-		Completed	-	-
NCT00835107	Depression, Bipolar	Phase 4	Completed	-	Canada, Ontario ... 展开 >> Providence Care Mental Health Services Kingston, Ontario, Canada, K7L 4X3 收起 <<
NCT01113541	Bipolar Disorder	Phase 3	Terminated(See termination rea... 展开 >>son in detailed description.) 收起 <<	-	Canada, Alberta ... 展开 >> Foothills Medical Centre, Department of Psychiatry Calgary, Alberta, Canada, T2N 2T9 Mental Health Centre for Research and Education Calgary, Alberta, Canada, T2N 2T9 Canada, British Columbia Dr. Alexander McIntyre Inc. Penticton, British Columbia, Canada, V2A 4M4 Canada, Manitoba Country Club Plaza Winnipeg, Manitoba, Canada, R3K 2E2 Edgeland Medical, Dr. Alla Kirshner Medical Corporation Winnipeg, Manitoba, Canada, R3P 0N5 Canada, Nova Scotia Capital, Health Authority, QE II Health Sciences Centre, Mood Disorder Clinic Halifax, Nova Scotia, Canada, B3H 2E2 Office of Dr. A. K. Munshi Sydney, Nova Scotia, Canada, B1S 2E8 Canada, Quebec Centre de recherche Fernand-Seguin de l'hopital Louis H. Lafontaine Montreal, Quebec, Canada, H1N 3V2 Clinique St-Leonard Montreal, Quebec, Canada, H1P 3K2 Diex Research Sherbrooke Inc. Sherbrooke, Quebec, Canada, J1H 1Z1 收起 <<
NCT01113541	-		Terminated(See termination rea... 展开 >>son in detailed description.) 收起 <<	-	-
NCT01198353	Schizophrenia ... 展开 >> Schizoaffective Disorder 收起 <<	Phase 4	Completed	-	Korea, Republic of ... 展开 >> Korea University Medical Center Ansan Hospital Ansan, Gyeonggi-do, Korea, Republic of, 425-707 Soonchunhyang University Bucheon Hospital Bucheon, Korea, Republic of, 420-767 Inha University Hospital Incheon, Korea, Republic of, 400-700 Catholic University Our Lady of Mercy Hospital Incheon, Korea, Republic of, 403-720 Korea University Medical Center Guro Hospital Seoul, Korea, Republic of, 152-703 Kangnam Sacred Heart Hospital Seoul, Korea, Republic of, 431-070 收起 <<
NCT00555997	-		Completed	-	-
NCT00555997	Major Depressive Disorder	Phase 2	Completed	-	United States, California ... 展开 >> Cedars-Sinai Medical Center Los Angeles, California, United States, 90048 United States, Connecticut University of Connecticut Health Center Farmington, Connecticut, United States, 06030-6415 Comprehensive Psychiatric Care Norwich, Connecticut, United States, 06360 United States, Illinois Psychiatric Medicine Associates, L.L.C. Chicago, Illinois, United States, 60612 United States, Massachusetts Massachusetts General Hosptial Boston, Massachusetts, United States, 02114 Cambridge Health Alliance Cambridge, Massachusetts, United States, 02139 United States, Tennessee Vanderbilt University Medical Center Nashville, Tennessee, United States, 37212 收起 <<
NCT01581866	Healthy	Phase 1	Completed	-	United States, Florida ... 展开 >> SFBC Ft. Myers, Inc. Fort Myers, Florida, United States, 33901 收起 <<
NCT02935998	Schizophrenia	Phase 4	Unknown	December 2017	China, Beijing ... 展开 >> Beijing Huilongguan Hospital Not yet recruiting Beijing, Beijing, China, 100096 Contact: Yang Fude, Director +8613651336121 yangfd200@126.com Contact: Zhang Qi, Residents +8613051296767 407291579@qq.com 收起 <<
NCT01581879	Healthy	Phase 1	Completed	-	United States, Florida ... 展开 >> SFBC Ft. Myers, Inc. Fort Myers, Florida, United States, 33901 收起 <<
NCT01714011	Schizophrenia	Phase 4	Completed	-	Malaysia ... 展开 >> University Malaya Medical Centre Kuala Lumpur, Malaysia, 59100 收起 <<
NCT00622739	-		Completed	-	-

Ziprasidone HCl monohydrate/佐帕司通 {[allProObj[0].p_purity_real_show]}

Ziprasidone HCl monohydrate/佐帕司通纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Ziprasidone HCl monohydrate/佐帕司通质控信息

Ziprasidone HCl monohydrate/佐帕司通生物活性

Ziprasidone HCl monohydrate/佐帕司通临床研究

Ziprasidone HCl monohydrate/佐帕司通参考文献

Ziprasidone HCl monohydrate/佐帕司通实验方案

Ziprasidone HCl monohydrate/佐帕司通技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Ziprasidone HCl monohydrate/佐帕司通 {[allProObj[0].p_purity_real_show]}

Ziprasidone HCl monohydrate/佐帕司通 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Ziprasidone HCl monohydrate/佐帕司通 质控信息

Ziprasidone HCl monohydrate/佐帕司通 生物活性

Ziprasidone HCl monohydrate/佐帕司通 临床研究

Ziprasidone HCl monohydrate/佐帕司通 参考文献

Ziprasidone HCl monohydrate/佐帕司通 实验方案

Ziprasidone HCl monohydrate/佐帕司通 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Ziprasidone HCl monohydrate/佐帕司通纯度/质量文件产品仅供科研

Ziprasidone HCl monohydrate/佐帕司通质控信息

Ziprasidone HCl monohydrate/佐帕司通生物活性

Ziprasidone HCl monohydrate/佐帕司通临床研究

Ziprasidone HCl monohydrate/佐帕司通参考文献

Ziprasidone HCl monohydrate/佐帕司通实验方案

Ziprasidone HCl monohydrate/佐帕司通技术信息